Their lead product candidate, BIO89-100, is a glycoPEGylated analog of FGF21, showing promising results in reducing liver fat and lipid markers in patients with NASH. They are also exploring its potential for severe hypertriglyceridemia. With operations in San Francisco and Israel, 89bio aims to address unmet medical needs in liver and metabolic disorders.